Amphastar Pharmaceuticals was founded in 1996 and is headquartered in Rancho Cucamonga, US

Amphastar Pharmaceuticals has an office in Rancho Cucamonga

Rancho Cucamonga, US (HQ)

11570 6th St

Amphastar Pharmaceuticals's revenue was reported to be $56.7 m in Q1, 2017

USD

## Revenue (Q1, 2017) | 56.7 m |

## Gross profit (Q1, 2017) | 22.8 m |

## Gross profit margin (Q1, 2017), % | 40% |

## Net income (Q1, 2017) | 893 k |

## EBIT (Q1, 2017) | 1.4 m |

## Market capitalization (22-Aug-2017) | 741.4 m |

## Cash (31-Mar-2017) | 76.8 m |

Amphastar Pharmaceuticals's current market capitalization is $741.4 m.

- Source: SEC Filings

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Revenue | 210.5 m | 251.5 m | 255.2 m |

## Revenue growth, % | 20% | 1% | |

## Cost of goods sold | 159.2 m | 174.2 m | 151 m |

## Gross profit | 51.3 m | 77.3 m | 104.2 m |

## Gross profit Margin, % | 24% | 31% | 41% |

## Sales and marketing expense | 5.6 m | 5.5 m | 5.5 m |

## R&D expense | 28.4 m | 37.1 m | 41.2 m |

## General and administrative expense | 34.8 m | 41.5 m | 41.8 m |

## Operating expense total | 68.8 m | 84 m | 88.5 m |

## EBIT | (18 m) | (6.9 m) | 15.7 m |

## EBIT margin, % | (9%) | (3%) | 6% |

## Interest expense | 609 k | 987 k | 1 m |

## Interest income | 243 k | 315 k | 270 k |

## Pre tax profit | (18.1 m) | (10.4 m) | 14.9 m |

## Income tax expense | (7.4 m) | (7.6 m) | 4.4 m |

## Net Income | (10.7 m) | (2.8 m) | 10.5 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Revenue | 49 m | 59.7 m | 56.9 m | 53.9 m | 63.9 m | 59.4 m | 68 m | 64.2 m | 56.7 m |

## Cost of goods sold | 34 m | 47.9 m | 43.6 m | 40.5 m | 46.3 m | 34.5 m | 36.3 m | 36.6 m | 33.8 m |

## Gross profit | 15 m | 11.8 m | 13.3 m | 13.3 m | 17.6 m | 24.9 m | 31.7 m | 27.6 m | 22.8 m |

## Gross profit Margin, % | 31% | 20% | 23% | 25% | 28% | 42% | 47% | 43% | 40% |

## R&D expense | 6 m | 8.6 m | 6.6 m | 10.7 m | 11.1 m | 8.4 m | 10.5 m | 9.7 m | 11.3 m |

## General and administrative expense | 8.6 m | 9.6 m | 12.5 m | 11.3 m | 9 m | 10.9 m | 9.5 m | 10.8 m | 11.3 m |

## Operating expense total | 14.6 m | 18.1 m | 19 m | 22 m | 20.2 m | 19.3 m | 19.9 m | 20.5 m | 22.6 m |

## EBIT | (1.2 m) | (7.8 m) | (7.3 m) | (10.3 m) | (3.7 m) | 4.1 m | 10.3 m | 5.8 m | 1.4 m |

## EBIT margin, % | (2%) | (13%) | (13%) | (19%) | (6%) | 7% | 15% | 9% | 2% |

## Interest expense | 476 k | 504 k | 341 k | 210 k | 232 k | 384 k | 305 k | 281 k | 191 k |

## Interest income | 32 k | 94 k | 92 k | 65 k | 83 k | 74 k | 50 k | 63 k | 91 k |

## Pre tax profit | (1.9 m) | (8 m) | (6.2 m) | (10.2 m) | (4.3 m) | 3.8 m | 9.8 m | 6 m | 1.5 m |

## Income tax expense | (696 k) | (2.6 m) | (5.5 m) | (3.6 m) | (1.3 m) | 1.3 m | 2.9 m | 2.1 m | 611 k |

## Net Income | (1.2 m) | (5.4 m) | (665 k) | (6.6 m) | (3 m) | 2.5 m | 6.9 m | 3.9 m | 893 k |

- Source: SEC Filings

USD | Y, 2012^{} | Y, 2013^{} | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|---|---|

## Cash | 50.2 m | 53.6 m | 67.8 m | 66.1 m | 72.4 m |

## Accounts Receivable | 22.9 m | 33.2 m | 26.8 m | ||

## Inventories | 118.4 m | ||||

## Current Assets | 198 m | 175.9 m | 184.1 m | ||

## PP&E | 138.3 m | 142.2 m | 152.9 m | ||

## Goodwill | 42.6 m | 39.9 m | 50.3 m | ||

## Total Assets | 389.4 m | 390.1 m | 427.7 m | ||

## Accounts Payable | 10.2 m | 13.9 m | 16.2 m | ||

## Current Liabilities | 62.6 m | 60 m | 60.6 m | ||

## Total Liabilities | 98.5 m | ||||

## Additional Paid-in Capital | 220.7 m | 247.8 m | 283.1 m | ||

## Retained Earnings | 63.1 m | 60.3 m | 70.9 m | ||

## Total Equity | 295.5 m | 329.3 m | |||

## Financial Leverage | 1.3 x | 1.3 x |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Cash | 64.1 m | 72.9 m | 68.6 m | 74.5 m | 76.8 m | ||||

## Accounts Receivable | 18.6 m | 26.6 m | 21.7 m | 19.8 m | 25 m | 23.1 m | 23.1 m | 26.6 m | 25.9 m |

## Inventories | 106 m | 88.1 m | 84.9 m | 80.2 m | 72.4 m | 82.2 m | 88.3 m | 90.7 m | 78.1 m |

## Current Assets | 214.2 m | 215.2 m | 202.6 m | 203.9 m | 199.1 m | 173.4 m | 181.3 m | 190.2 m | 191.4 m |

## PP&E | 134 m | 134.1 m | 138.3 m | 139.3 m | 141.2 m | 144.7 m | 148.6 m | 152 m | 157.4 m |

## Goodwill | 39.3 m | 43.2 m | 41.3 m | 40.9 m | 40.5 m | 44 m | 43.3 m | 51.7 m | 46 m |

## Total Assets | 397.3 m | 401.1 m | 396.5 m | 398.9 m | 395 m | 395 m | 408.6 m | 428.8 m | 435.6 m |

## Accounts Payable | 17.8 m | 10 m | 18.9 m | 18.4 m | 12.3 m | 18.6 m | 18.8 m | 13.4 m | 19.3 m |

## Current Liabilities | 56.3 m | 63.1 m | 72.1 m | 69.4 m | 70.7 m | 64.9 m | 65.7 m | 60.8 m | 72.9 m |

## Additional Paid-in Capital | 217 m | 219.3 m | 223.3 m | 236.7 m | 240.7 m | 250.7 m | 258.8 m | 276.5 m | 285.4 m |

## Retained Earnings | 71 m | 65.6 m | 62.4 m | 55.8 m | 52.8 m | 62.8 m | 69.7 m | 73.6 m | 72.6 m |

## Total Equity | 285.3 m | 283.8 m | 296.6 m | 307.5 m | 328.5 m | 325.6 m | |||

## Financial Leverage | 1.4 x | 1.4 x | 1.3 x | 1.3 x | 1.3 x | 1.3 x |

USD | FY, 2014^{} | FY, 2015^{} | FY, 2016^{} |
---|---|---|---|

## Net Income | (10.7 m) | (2.8 m) | 10.5 m |

## Depreciation and Amortization | 12 m | ||

## Accounts Receivable | 1.2 m | 6.4 m | |

## Inventories | 9.1 m | (9.7 m) | |

## Accounts Payable | 7 m | ||

## Cash From Operating Activities | 14.2 m | (1.8 m) | 38.6 m |

## Purchases of PP&E | (18.7 m) | ||

## Cash From Investing Activities | (39.8 m) | (39.5 m) | |

## Long-term Borrowings | (8.2 m) | (14.7 m) | |

## Cash From Financing Activities | 32.1 m | 7.1 m | |

## Interest Paid | 2.6 m | ||

## Income Taxes Paid | 436 k | 3.4 m |

USD | Q2, 2014^{} | Q3, 2014^{} | Q1, 2015^{} | Q2, 2015^{} | Q3, 2015^{} | Q1, 2016^{} | Q2, 2016^{} | Q3, 2016^{} | Q1, 2017^{} |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (1.2 m) | (5.4 m) | (665 k) | (6.6 m) | (3 m) | 2.5 m | 6.9 m | 3.9 m | 893 k |

## Accounts Receivable | 18.6 m | 26.6 m | 21.7 m | 19.8 m | 25 m | 23.1 m | 23.1 m | 26.6 m | 25.9 m |

## Accounts Payable | 17.8 m | 10 m | 18.9 m | 18.4 m | 12.3 m | 18.6 m | 18.8 m | 13.4 m | 19.3 m |

USD | Y, 2017 |
---|---|

## Revenue/Employee | 37.8 k |

## Financial Leverage | 1.3 x |

Source: 12 public H-1B filings from Amphastar Pharmaceuticals

July 17, 2016

Aimee Dunkle began helping to distribute the drug naloxone -- the life-saving antidote to prescription painkiller overdoses -- after her son died. Ben Dunkle, 20, was with three people when he overdosed in 2012, she said. She believes he would be alive today if they had naloxone. “They panicked,…